ATE460943T1 - Therapeutische mittel als antikrebs impfstoffadjuvantien und deren therapeutische verfahren - Google Patents

Therapeutische mittel als antikrebs impfstoffadjuvantien und deren therapeutische verfahren

Info

Publication number
ATE460943T1
ATE460943T1 AT03707982T AT03707982T ATE460943T1 AT E460943 T1 ATE460943 T1 AT E460943T1 AT 03707982 T AT03707982 T AT 03707982T AT 03707982 T AT03707982 T AT 03707982T AT E460943 T1 ATE460943 T1 AT E460943T1
Authority
AT
Austria
Prior art keywords
cancer vaccine
therapeutic
vaccine adjuvants
therapeutic agents
methods
Prior art date
Application number
AT03707982T
Other languages
English (en)
Inventor
Eric Simard
Philippe Goyette
Pierre Lemieux
Original Assignee
Technologie Biolactis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technologie Biolactis Inc filed Critical Technologie Biolactis Inc
Application granted granted Critical
Publication of ATE460943T1 publication Critical patent/ATE460943T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03707982T 2002-03-25 2003-03-25 Therapeutische mittel als antikrebs impfstoffadjuvantien und deren therapeutische verfahren ATE460943T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36653102P 2002-03-25 2002-03-25
PCT/CA2003/000434 WO2003080111A2 (en) 2002-03-25 2003-03-25 Chemotherapeutic agents as anti-cancer vaccine adjuvants and therapeutic methods thereof

Publications (1)

Publication Number Publication Date
ATE460943T1 true ATE460943T1 (de) 2010-04-15

Family

ID=28454811

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03707982T ATE460943T1 (de) 2002-03-25 2003-03-25 Therapeutische mittel als antikrebs impfstoffadjuvantien und deren therapeutische verfahren

Country Status (7)

Country Link
US (2) US20060051354A1 (de)
EP (1) EP1490098B1 (de)
AT (1) ATE460943T1 (de)
AU (1) AU2003212170A1 (de)
CA (1) CA2479528A1 (de)
DE (1) DE60331725D1 (de)
WO (1) WO2003080111A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8128922B2 (en) 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
WO2004098526A2 (en) 2003-05-05 2004-11-18 Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
AU2005322960A1 (en) 2005-01-06 2006-07-13 The Johns Hopkins University RNA interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by DNA and transfected dendritic cell vaccines
GB0519303D0 (en) * 2005-09-21 2005-11-02 Oxford Biomedica Ltd Chemo-immunotherapy method
KR101399591B1 (ko) * 2005-11-02 2014-06-18 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 동시 화학요법 및 면역요법
EP1955708A4 (de) * 2005-11-24 2013-02-06 Dainippon Sumitomo Pharma Co Neuer memory-ctl-induktionspotentiator
WO2008024844A2 (en) * 2006-08-22 2008-02-28 The Johns Hopkins University Anticancer combination therapies
WO2008121461A2 (en) * 2007-02-26 2008-10-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Vaccine for activating helper function of cd8+ tcells
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
CN101766815B (zh) * 2009-12-31 2012-04-25 胡松华 紫杉醇及多西紫杉醇的用途
WO2012054425A2 (en) * 2010-10-18 2012-04-26 University Of Iowa Research Foundation Biodegradable particulate formulations
ES2702622T3 (es) * 2013-03-27 2019-03-04 Immunovaccine Technologies Inc Método para mejorar la eficacia de una vacuna de survivina en el tratamiento de cáncer
JP6813258B2 (ja) * 2014-12-11 2021-01-13 リティックス バイオファーマ エイエス 化学療法の組み合わせ
WO2016168361A1 (en) * 2015-04-14 2016-10-20 Polynoma, Llc Polyvalent vaccines and combination therapy for the treatment of melanoma
US20220370496A1 (en) * 2019-09-13 2022-11-24 H. Lee Moffitt Cancer Center And Research Institute, Inc. Her3 pulsed dc1 therapy
CN111518169B (zh) * 2020-04-29 2021-07-06 潍坊医学院 一种多肽、多肽纳米载药载体及两者的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5717092A (en) * 1996-03-29 1998-02-10 Vertex Pharmaceuticals Inc. Compounds with improved multi-drug resistance activity
US6277368B1 (en) * 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
AU4818297A (en) * 1996-10-16 1998-05-11 Johns Hopkins University, The Cytokine enhanced immunotherapy for brain tumors

Also Published As

Publication number Publication date
AU2003212170A1 (en) 2003-10-08
US20060051354A1 (en) 2006-03-09
EP1490098B1 (de) 2010-03-17
EP1490098A2 (de) 2004-12-29
WO2003080111A2 (en) 2003-10-02
DE60331725D1 (de) 2010-04-29
WO2003080111A3 (en) 2003-11-13
CA2479528A1 (en) 2003-10-02
AU2003212170A8 (en) 2003-10-08
US20100272676A1 (en) 2010-10-28

Similar Documents

Publication Publication Date Title
ATE460943T1 (de) Therapeutische mittel als antikrebs impfstoffadjuvantien und deren therapeutische verfahren
TW200602077A (en) Compositions as adjuvants to improve immune responses to vaccines and methods of use
EA200702633A1 (ru) Вакцина против малярии
DK1187629T3 (da) Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
ATE499112T1 (de) Immunologische verwendungen von immunmodulatorischen verbindungen für einen impfstoff und therapie gegen infektionskrankheiten
DE60043708D1 (de) Verfahren zur erhaltung zellimmuneantworten gegen proteinen
LU92262I2 (fr) Vaccin méningococcique groupe B (ADNr, composant, adsorbé) et ses dérivés pharmaceutiquement acceptables (BEXSERO)
GB0109297D0 (en) Vaccine
DK1565471T3 (da) Quionolinylpyrazoler
DE60331412D1 (de) Hiv-vakzine und anwendungsverfahren
IL173481A0 (en) Polysaccharide double-layer microcapsules as carriers for biologically active substance oral administration
EA200701166A1 (ru) Альфа-тимозиновые пептиды в качестве адъювантов противораковых вакцин
DE60137146D1 (de) Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten
SG153661A1 (en) Formulation and methods for the treatment of thrombocythemia
EA200700017A1 (ru) Способ усиления иммунного ответа на вакцину
WO2002053176A3 (en) An autologous anti-cancer vaccine
WO2003103570A3 (en) TRANSCUTANEOUS IMMUNIZATION AGAINST PAPILLOMAVIRUS WITH A PAPILLOMAVIRUS VIRUS
DE60330004D1 (de) Impfung mit immunisolierten und einen immunomodulator produzierenden zellen
WO2002030458A8 (en) Yersinia adhesion protein as vaccine adjuvant
PL358081A1 (en) Inclusion bodies as antigenes in oral immunization of animals
DE60042776D1 (de) Lipoglykan zusammensetzungen und methoden zur behandlung von parasitischen infektionen
WO2002100317A3 (en) Targeted particles and methods of using the same
WO2003032895A3 (en) Methods and pharmaceutical compositions for stimulating the immune system and/or treating cancer
RU2002102522A (ru) Способ вакцинопрофилактики вирусных болезней телят

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties